We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Galapagos and Opsona Therapeutics Initiate Drug Discovery Collaboration
News

Galapagos and Opsona Therapeutics Initiate Drug Discovery Collaboration

Galapagos and Opsona Therapeutics Initiate Drug Discovery Collaboration
News

Galapagos and Opsona Therapeutics Initiate Drug Discovery Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Galapagos and Opsona Therapeutics Initiate Drug Discovery Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Galapagos NV has announced that it has initiated an integrated drug discovery collaboration with Opsona Therapeutics (Dublin, Ireland).

Under the terms of the agreement, Galapagos' service division BioFocus DPI will perform biology, medicinal chemistry and ADME/PK services for an Opsona drug discovery program. Opsona will make research payments to BioFocus DPI and fund the work of 4 to 5 BioFocus DPI scientists in 2009.

"We are pleased to add Opsona Therapeutics, an emerging biotech with a promising pipeline and a successful follow-on financing round, to the growing list of BioFocus DPI customers," said Onno van de Stolpe, CEO of Galapagos. "BioFocus DPI continues to attract top biotech, pharma and not-for-profit organizations as partners, resulting in one of the most well-rounded client bases in the business."
Advertisement